Clinical Trial Update: Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone

View source ↗

Summary

The update announces an Expanded Access Program in the United States to allow patients with Idiopathic Pulmonary Fibrosis to access Pirfenidone.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• PIRFENIDONE (pirfenidone)

Snippet

Sponsor: Genentech, Inc. | Conditions: Idiopathic Pulmonary Fibrosis | Status: APPROVED_FOR_MARKETING